Sign in
KB

Krystal Biotech, Inc. (KRYS)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 delivered strong top-line and profitability: revenue rose 116% YoY to $91.1M with 95% gross margin and diluted EPS of $1.52; sequential revenue growth persisted for the sixth straight quarter, supported by high patient persistence and broad U.S. access for VYJUVEK .
  • Global expansion is at the doorstep: management expected a CHMP opinion in 1Q25 on the call and subsequently received a positive CHMP opinion on Feb 28; first EU launch targeted for mid‑2025, with Japan decision expected 2H25—key stock catalysts into 2025 .
  • 2025 non‑GAAP OpEx guidance (R&D+SG&A) set at $150–$175M, reflecting ex‑U.S. launch investment and pipeline advancement; cash and investments ended Q4 at $749.6M, providing ample flexibility (buyback discussed in Q&A) .
  • Pipeline momentum continued in Q4: KB408 AATD data showed lung gene delivery and functional AAT at therapeutic levels; KB707 inhaled monotherapy produced early clinical activity in advanced NSCLC; KB407 CF Phase 1 moving into molecular readout mid‑2025—broadening optionality beyond dermatology .

What Went Well and What Went Wrong

  • What Went Well

    • Commercial execution: Q4 VYJUVEK revenue climbed to $91.1M, gross margin reached 95%, and diluted EPS was $1.52, marking the fourth consecutive quarter of sequential earnings growth .
    • Access and persistence: >510 reimbursement approvals as of February with ~97% payer lives covered and 85% weekly‑on‑drug compliance; 97% of doses administered at home, underscoring convenience and patient preference .
    • Global/regulatory steps: CHMP positive opinion recommending EU approval (includes home dosing/patient or caregiver administration), positioning Germany launch for mid‑2025; Japan NDA review on track for 2H25 decision .

  • What Went Wrong

    • Holiday/seasonality friction: management cited Q4 holiday‑related slowdowns affecting prescriber office activity and payer responses; January reverification season also created delays, though momentum resumed into early 2025 .
    • Slight compliance moderation: weekly‑on‑drug compliance trended from 90% (Q2) to 87% (Q3) to 85% (Q4) as some patients pause therapy after wound closure before resuming for maintenance—favorable clinically but can temper dose cadence .
    • Competitive overhang: potential DEB competition as early as 2Q was raised in Q&A; management is engaging physicians/patients and remains confident in VYJUVEK’s value proposition and 2‑year penetration goals .

Financial Results

Quarterly P&L (USD)

MetricQ2 2024Q3 2024Q4 2024
Revenue ($M)$70.3 $83.8 $91.1
Cost of Goods Sold ($M)$6.0 $6.7 $4.9
Gross Margin (%)91% 92% 95%
R&D ($M)$15.6 $13.5 $13.5
SG&A ($M)$27.6 $28.7 $31.3
Operating Income ($M)$8.6 $22.4 $41.4
Net Income ($M)$15.6 $27.2 $45.5
Diluted EPS ($)$0.53 $0.91 $1.52

YoY Comparison (Q4 2024 vs Q4 2023)

MetricQ4 2023Q4 2024YoY Change
Revenue ($M)$42.1 $91.1 +116%
COGS ($M)$2.9 $4.9 +$2.1M
Gross Margin (%)93% 95% +200 bps
R&D ($M)$11.4 $13.5 +$2.2M
SG&A ($M)$24.8 $31.3 +$6.5M
Net Income ($M)$8.7 $45.5 +$36.8M
Diluted EPS ($)$0.30 $1.52 +$1.22

Balance Sheet Liquidity

MetricQ2 2024Q3 2024Q4 2024
Cash & Investments ($M)$628.9 $694.2 $749.6
Cash and Cash Equivalents ($M)$345.8 $374.0 $344.9
Short‑Term Investments ($M)$213.8 $214.4 $252.7
Long‑Term Investments ($M)$69.3 $105.9 $152.1

KPIs and Commercial Metrics

KPIQ2 2024Q3 2024Q4 2024 / Early 2025
U.S. Reimbursement Approvals (cumulative)>400 (as of July) >460 (as of Oct) >510 (as of Feb)
Weekly‑on‑drug Compliance (%)90% 87% 85%
Home Administration Share (%)——~97% of weekly treatments

Estimates vs. Actuals

  • S&P Global consensus estimates were unavailable at the time of analysis due to data access limits. As a result, we cannot quantify beat/miss vs. Street for Q4 2024. Management noted gross-to-net stability and no revenue volatility tied to price cap accruals, which may have reduced quarter-end variability .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Non‑GAAP R&D + SG&AFY 2025N/A$150–$175M (ex‑SBC) New
Commentary——Increase vs. 2024 driven by ex‑U.S. commercial launch costs and pipeline advancement —

Note: Non‑GAAP combined R&D+SG&A excludes stock‑based compensation; no GAAP reconciliation provided due to uncertainty in SBC .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 2024)Previous Mentions (Q3 2024)Current Period (Q4 2024)Trend
EU/Japan expansionEMA MAA decision anticipated 2H24; JNDA filing planned 2H24 CHMP opinion before YE; first EU launch 1H25; JNDA filed; PMDA decision 2H25 Expected CHMP opinion 1Q25; later achieved positive CHMP (2/28); EU launch mid‑2025; Japan 2H25 Slight delay, now positive outcome; launch imminent
U.S. access/approvals>400 approvals; 97% covered lives >460 approvals; 97% covered lives >510 approvals (Feb); broad access maintained Improving penetration
Patient persistence/home dosingCompliance 90% Compliance 87% Compliance 85%; ~97% home dosing Slight compliance moderation with pauses; high home use sustained
Gross margin trajectory91% 92% 95% Improving COGS leverage
Respiratory pipeline (KB407/KB408)KB407: CF Phase 1 advancing; KB408: Phase 1 progressing Interim updates guided before YE/1H25 KB408: lung gene delivery and functional AAT; KB407: safety, TDN sanction, Cohort 3 molecular mid‑2025 Clear validation; next data in 2025
Oncology (KB707 inhaled)Dose expansion initiated Initial data guided before YE NSCLC monotherapy: 27% ORR, 73% DCR; moving to combos Early signal supports expansion
Manufacturing scale-up——FDA‑approved process scale‑up; platform CMC de‑risking Capacity/CMC readiness improved
Price cap/revenue stability——Accruals managed to avoid revenue volatility Stable GTN dynamics

Management Commentary

  • “Net VYJUVEK revenue for the Q came in at $91.1 million, bringing revenue for 2024 to $290.5 million. Gross margins and GTN were consistent with prior Qs.”
  • “We expect a positive CHMP opinion… and our first EU launch in Germany around midyear… In Germany and France alone, there are over 1,000 identified DEB patients.”
  • “Patient preference for at‑home administration is again effectively unchanged with 97% of the weekly treatments occurring in the home setting. Patient to weekly treatments while on drug was 85% as of the end of the fourth quarter.”
  • “We have done a terrific job of accruing for the price cap of VYJUVEK. We've had no volatility in net revenues in 2024 and we do not expect to have any going forward.”
  • On AATD: “Clear evidence of successful gene delivery… Free AAT levels… increased over 8‑fold… percentage of active, unbound neutrophil elastase dropping from 97.2% to 40.2% after a single KB408 dose.”

Q&A Highlights

  • Inventory/stocking and price cap: No unusual stocking in Q4; price cap accrual methodology designed to minimize revenue volatility; ~8% of commercial patients on the cap in 2024 .
  • EU market sizing and pricing: ~600 identified patients in Germany and ~400 in France; Germany launches at U.S. price for first 6 months before AMNOG negotiation; France AP program accrual from day one with pricing 15–18 months post‑approval .
  • Mix (dominant vs recessive): Higher dominant mix observed in Q4; management does not expect material compliance differences and sees quarterly variation .
  • Capital allocation: Company is seriously evaluating a share repurchase program; timing/size under consideration .
  • Manufacturing changes: Process scale‑up to larger bioreactors approved via supplement; platform‑wide CMC de‑risking benefits other programs (e.g., KB407) .
  • CF endpoints/strategy: For null population, even modest FEV1 gains (3–10%) could be meaningful; redosable approach aims to build function over time; potential biomarker strategy to reduce bronchoscopic burden .

Estimates Context

  • S&P Global consensus estimates were unavailable at the time of analysis due to data access constraints, so we cannot quantify Q4 revenue/EPS beat or miss. Given stable GTN and price cap accrual practices, quarter‑to‑quarter variability appears contained, but we recommend revisiting estimate comparisons once S&P Global data are accessible .

Key Takeaways for Investors

  • Sequential growth and margin expansion continue: Q4 revenue of $91.1M and 95% GM drove EPS to $1.52; operating leverage evident as SG&A rises for ex‑U.S. buildout but margins improved .
  • Near‑term catalyst path is clear: Post‑call positive CHMP opinion sets up Germany launch mid‑2025; France access and Japan decision in 2H25 can re‑accelerate growth and diversify revenue geographically .
  • Durable commercial model: >510 approvals, high home dosing (~97%), and managed price cap accruals support revenue durability and predictability through seasonal noise .
  • Pipeline is de‑risking lung as a second tissue: KB408 showed functional AAT in lung and neutrophil elastase reduction; KB407 CF moving to molecular endpoints mid‑2025; oncology KB707 inhaled monotherapy signal provides optionality .
  • 2025 OpEx step‑up is purposeful: Non‑GAAP R&D+SG&A guidance of $150–$175M funds ex‑U.S. launches and clinical milestones; $749.6M in liquidity provides cushion and buyback potential .
  • Competitive watch: Potential DEB competitors in 2025; management confidence rests on efficacy, convenience, and home dosing—monitor market share as rivals emerge .
  • Trading lens: EU approval and first sales, Japan decision, and mid‑year respiratory readouts are likely stock movers; absence of revenue volatility from price cap accruals may reduce downside gap risk around quarters .

References:

  • Q4 2024 8‑K press release and financials
  • Q4 2024 earnings call transcript –
  • Q4‑period press releases (KB408/KB407 Dec 12; KB707 Dec 18) – –
  • Q3 2024 press release –
  • Q2 2024 8‑K press release –
  • CHMP positive opinion press release (post‑Q4) –
  • Duplicate standalone Q4 press release –